MARKET

CTNM

CTNM

Contineum Therapeutics
NASDAQ
4.350
+0.510
+13.28%
After Hours: 4.370 +0.02 +0.46% 19:37 07/18 EDT
OPEN
3.870
PREV CLOSE
3.840
HIGH
4.410
LOW
3.860
VOLUME
2.48M
TURNOVER
--
52 WEEK HIGH
21.92
52 WEEK LOW
3.350
MARKET CAP
112.54M
P/E (TTM)
-2.2533
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at CTNM last week (0707-0711)?
Weekly Report · 4d ago
Weekly Report: what happened at CTNM last week (0630-0704)?
Weekly Report · 07/07 12:18
Weekly Report: what happened at CTNM last week (0623-0627)?
Weekly Report · 06/30 12:28
Contineum Therapeutics Holds 2025 Annual Stockholders Meeting
TipRanks · 06/26 20:32
Positive Outlook for Contineum Therapeutics Amidst Minor Trial Delays
TipRanks · 06/25 17:05
Contineum completes enrollment for cohorts of PIPE-791 trial
TipRanks · 06/25 12:35
Contineum Therapeutics Completes PrMS And Healthy Volunteer Enrollment In Phase 1b PET Trial Of PIPE-791
Benzinga · 06/25 12:16
CONTINEUM THERAPEUTICS PROVIDES UPDATE ON PHASE 1B POSITRON EMISSION TOMOGRAPHY (PET) TRIAL OF PIPE-791
Reuters · 06/25 12:15
More
About CTNM
Contineum Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which is engaged in developing novel, oral small molecule therapies for neuroscience, inflammation and immunology (NI&I) indications with significant unmet need. It is advancing a pipeline of internally developed programs with multiple drug candidates in clinical trials. Its lead asset, PIPE-791, is a novel, brain-penetrant, small-molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) in development for idiopathic pulmonary fibrosis (IPF), progressive multiple sclerosis (PrMS), and chronic pain. Its second drug candidate, PIPE-307, is a novel, small-molecule selective inhibitor of the muscarinic type 1 receptor (M1R), in development for depression and relapse-remitting multiple sclerosis (RRMS). The Company is also conducting preclinical and discovery-phase experiments targeting other NI&I indications where its internally discovered molecules may have therapeutic potential.

Webull offers Contineum Therapeutics Inc stock information, including NASDAQ: CTNM real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CTNM stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading CTNM stock methods without spending real money on the virtual paper trading platform.